Trial Profile
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Germ cell cancer; Male breast cancer; Malignant melanoma; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- 09 Jul 2020 Results (n=196) assessing association of neutropenia with disease response to palbociclib in two studies (NCT01037790 & NCT01209598), published in the British Journal of Cancer.
- 03 Apr 2020 Status changed from recruiting to completed.
- 20 Aug 2018 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2019.